Harel Insurance Investments & Financial Services Ltd. Replimune Group, Inc. Transaction History

Harel Insurance Investments & Financial Services Ltd.

$5.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Jul 19, 2022	SELL	$13.32 - $19.98 $1,172 - $1,758	-88 Closed	0 $0
Q1 2022 May 03, 2022	BUY	$15.24 - $29.75 $1,341 - $2,618	88 New	88 $1,000

Others Institutions Holding REPL

# of Institutions

149

Shares Held

68M

Call Options Held

52.3K

Put Options Held

80.3K

Baker Bros. Advisors LP New York, NY

11M
Shares

$141 Million
1.3% of portfolio
Price T Rowe Associates Inc Baltimore, MD

9.88M
Shares

$126 Million
0.01% of portfolio
Fcpm Iii Services B.V. Naarden, P7

4.87M
Shares

$62.2 Million
9.16% of portfolio
Redmile Group, LLC San Francisco, CA

4.78M
Shares

$61.2 Million
3.43% of portfolio
Black Rock Inc. New York, NY

4.71M
Shares

$60.3 Million
0.0% of portfolio

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.

Account